1. Home
  2. BP vs VRTX Comparison

BP vs VRTX Comparison

Compare BP & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BP p.l.c.

BP

BP p.l.c.

HOLD

Current Price

$44.73

Market Cap

96.5B

Sector

Energy

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$453.58

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BP
VRTX
Founded
1889
1989
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Integrated oil Companies
EDP Services
Sector
Energy
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
96.5B
115.7B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
BP
VRTX
Price
$44.73
$453.58
Analyst Decision
Buy
Buy
Analyst Count
9
29
Target Price
$41.92
$539.08
AVG Volume (30 Days)
10.9M
1.1M
Earning Date
04-28-2026
05-04-2026
Dividend Yield
4.27%
N/A
EPS Growth
N/A
836.54
EPS
N/A
15.32
Revenue
N/A
$2,488,652,000.00
Revenue This Year
$0.19
$10.79
Revenue Next Year
$0.79
$10.14
P/E Ratio
$11,332.35
$29.87
Revenue Growth
N/A
46.20
52 Week Low
$25.22
$362.50
52 Week High
$46.79
$513.98

Technical Indicators

Market Signals
Indicator
BP
VRTX
Relative Strength Index (RSI) 71.94 43.06
Support Level $33.17 $443.06
Resistance Level N/A $473.78
Average True Range (ATR) 0.88 15.65
MACD 0.47 -3.78
Stochastic Oscillator 76.47 8.17

Price Performance

Historical Comparison
BP
VRTX

About BP BP p.l.c.

BP is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, it produced 1.2 million barrels of liquids and 6.9 billion cubic feet of natural gas per day. At the end of 2024, reserves stood at 6.2 billion barrels of oil equivalent, 59% of which are liquids. The company operates refineries with a capacity of 1.6 million barrels of oil per day.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: